|
| Blood disorders | MiR-15/107 group alterations | Abnormalities associated | Effects of miRNAs |
|
| AML | MiR-15a/16 decreased in (11q23) AML patients [82], elevated in patients with complete remission, and decreased with relapse [83] | | MiR-15a/16 enhanced ATRA effects inducing AML cell differentiation [83] |
|
| APL | MiR-15a/16 upregulation and miR-107 downregulation in a cohort of APL patients [135] | | Patients showed increased miR-15/107 during remission, and miR-15/107 upregulation was induced by ATRA in vitro in APL cells [135] |
|
| MiR-15a/16 underexpressed in CLL patients with 13q14 deletion and NZB mice (CLL model) [96, 99] | Uncontrolled B-1 cell proliferation [97] | Overexpression of miR-15a/16 in CLL murine model resulted in exclusive elimination of malignant B-1 cells [136] |
| CLL | MiR-195 upregulation reported from a study of 9 CLL patients compared to normal controls [137] | | Not determined |
| MiR-107 downregulated in CLL patients [138] | | Underexpression of miR-107 resulted in overexpression of oncogenic PLAG-1 protein [138] |
|
| MM | MiR-15a/16 decreased in MM patients [62] | Uncontrolled clonal plasma cell proliferation and proangiogenesis in bone marrow [62] | MiR-15a/16 targeted cell cycle regulators, inhibited NF-κB pathway, and downregulated proangiogenic genes [62] |
|
| SLE | miR-15a upregulated in spleen cells from NZB/NZW F1 mice (SLE model), when disease fully developed (manuscript accepted for publication) | Elevated autoreactive antibody producing cells terminally differentiated plasma cells | MiR-15a enhanced plasma cell differentiation |
|
